Please login to the form below

Not currently logged in
Email:
Password:

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

Boehringer Ingelheim headquarters

Boehringer Ingelheim will next week mark another milestone in its oncology ambitions when it launches its first cancer drug in the US.

Gilotrif (afatinib) received FDA approval in July to treat patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations.

The personalised cancer drug was approved alongside a companion diagnostic developed by Qiagen to detect the presence of EGFR mutations.

Boehringer plans to support the launch of Gilotrif with a “comprehensive patient support programme” of access and clinical support services, including financial support.

Gilotrif's passage through the FDA regulatory process was a relatively speedy one, with the drug granted priority review in January this year due to the urgent need for new treatments in NSCLC, which accounts for about 85 per cent of all lung cancers.

In Europe, where it is set to be branded as Giotrif, afatinib last month received the backing of EMA scientific advisors at the Committee for Healthcare and Medical Products, putting it on course for full approval by December.

The company is also investigating the drug in breast cancer and head and neck cancer, while elsewhere its oncology pipeline includes the angiogenesis inhibitor nintedanib, in phase III trials for NSCLC and ovarian cancer, and polo-like kinase 1 (Plk1) inhibitor volasertib, which is in phase II testing for acute myeloid leukaemia.

Article by
Dominic Tyer

29th August 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics